BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10764695)

  • 1. Is there still a need for albumin infusions to treat patients with liver disease?
    Ginès P; Arroyo V
    Gut; 2000 May; 46(5):588-90. PubMed ID: 10764695
    [No Abstract]   [Full Text] [Related]  

  • 2. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 3. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.
    Arroyo V; Colmenero J
    J Hepatol; 2003; 38 Suppl 1():S69-89. PubMed ID: 12591187
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vasoconstrictors in the treatment of hepatorenal syndrome].
    Ortega R; Calahorra B; Ginès P
    Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 7.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
    Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
    Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
    Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials.
    Mookerjee RP; Jalan R
    Crit Care; 2008; 12(2):119. PubMed ID: 18394181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of ascites and hepatorenal syndrome.
    Piano S; Tonon M; Angeli P
    Hepatol Int; 2018 Feb; 12(Suppl 1):122-134. PubMed ID: 28836115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatorenal syndrome].
    Bosma JW; van Meyel JJ; Siegert CE
    Ned Tijdschr Geneeskd; 2010; 154():A1355. PubMed ID: 20456764
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of cirrhosis and ascites.
    Ginès P; Cárdenas A; Arroyo V; Rodés J
    N Engl J Med; 2004 Apr; 350(16):1646-54. PubMed ID: 15084697
    [No Abstract]   [Full Text] [Related]  

  • 14. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment.
    Ginès P; Fernández-Esparrach G; Arroyo V
    Baillieres Clin Gastroenterol; 1997 Jun; 11(2):365-85. PubMed ID: 9395753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
    Singh V; Kumar R; Nain CK; Singh B; Sharma AK
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hepatorenal syndrome].
    Guevara M
    Gastroenterol Hepatol; 2003 Apr; 26(4):270-4. PubMed ID: 12681123
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
    Umgelter A; Reindl W; Wagner KS; Franzen M; Stock K; Schmid RM; Huber W
    Crit Care; 2008; 12(1):R4. PubMed ID: 18197961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
    Saló J; Ginès A; Quer JC; Fernández-Esparrach G; Guevara M; Ginès P; Bataller R; Planas R; Jiménez W; Arroyo V; Rodés J
    J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites and hepatorenal syndrome: pathogenesis and treatment strategies.
    Ginès P; Arroyo V; Rodés J
    Adv Intern Med; 1998; 43():99-142. PubMed ID: 9506180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.